Medical Health
Resume:
Curriculum Vitae,
Wil Milhous
January ****
Wilbur Kearse Milhous
Professor and Associate Dean for Research
College of Public Health
University of South Florida
***** ***** *. ***** ******ard, MDC 56, Tampa, FL 33612
Phone 813-***-**** Fax: 813-***-****
Email: abo3hv@r.postjobfree.com
Global Health Infectious Disease Research (GHIDR) Program, Interdisciplinary Research
Building
(IDRB) 3720 Spectrum Blvd, Suite 304, Tampa, FL 33612 Phone 813-***-****
Personal Information:
Married: Virginia Graves Milhous
Children: Elizabeth E. Milhous and Allyson Milhous Best
Education
PhD, 1983, School of Public Health, Univers ity of North Carolina, Chapel Hill, NC.
Dissertation: Quantitative assessment of the inte ractions and activities of combinations
of
antimalarials in continuous culture of Plasmodium falciparum
Wellcome Scholar, Earned BG Greenberg Award for Excellence in Doctoral Research
Mentors: NF Weatherly (School of Public Health), RE Desjardins (Burroughs Wellcome)
and JH Bowdre (School of Medicine)
BS, MS, College of Agriculture and Biological Sciences, Clemson University, Clemson, SC
MS Thesis: Studies on the development of Coccidia in cell culture.
Mentors: Don Turk & John Bond (Clemson) and J. Solis (Merck)
Professional Certification
Fellow, American Academy of Microbiology, 1992-
Medical & Public Health Microbiology: Diplomate, American Board of Medical Microbiology
(ABMM),
1995. Certificate No. 872 with Re-Certification through December 2010
Public Health: Specialist in Public Health & Medical Laboratory Microbiology, National
Registry of
Microbiologist, NRM Certificate No.1250 with Re-Certification through December 2010
Clinical Pathology: American Society for Clinical Pathology
ASCP Certificate No. S2909 with Re-Certification through December 2010
Experience:
July 2007- Professor of Global Health and Associate Dean for Research, College of Public
Health,
University of South Florida, Tampa, Florida. Develop strategic plans for enhancing
research productivity within the College while facilitating collaboration with other
colleges and programs within USF Health and the University at large. Develop and
implement a comprehensive strategy for faculty development.
Affiliations: Center for Biological Defense (CBD); Center for Molecular Diversity in
Drug Design, Discovery, and Delivery (CMD5) ; Center of Excellence for Biomolecular
Identification and Targeted Therapeutics (B ITT); Patel Center for Global Solutions
Joint Appointment: Professor, College of Medicine, Department of Internal Medicine,
Signature Interdisciplinary Program in Allergy, Immunology and Infectious Disease
1
Curriculum Vitae, Wil Milhous
January 2008
2002-2007Research Coordinator, Department of Defense Military Infectious Disease
Research
Program (midrp.org). Plan and direct research training, basic and translational research,
patient diagnosis and clinical trials in a multidisciplinary program to develop new
therapies for the prevention and treatment of tropical emerging diseases, chemical and
biological threat agents. Integrate and coordinate all aspects of research and
development
including management of technology, process, budget, personnel, integrated product
development teams and interface with human use and institutional review boards, Food
and Drug Administration, collaborating agen cies and global co-development partners.
Write and implement strategic plans to balan ce research portfolios with global marketing
analysis and unmet medical needs. Chief Scientific Officer for Therapeutics, Walter
Reed Army Institute of Research, Silver Sp ring, MD, and for Army (Bangkok, Brisbane,
Nairobi) and Navy (Cairo, Jakarta, Lima) overseas research labs.
2002-2003Laboratory Director (College of Amer ican Pathology Approved) with principle
responsibilities for diagnosis of Leishmaniasis.
1990-2007Associate Professor, Department of Preventive Medicine & Biometrics with joint
teaching appointments in Clinical Phar macology and Microbiology & Immunology,
Uniformed Services University, Bethesda, MD.
1997-2002Director for Experimental Therapeutics, Walter Reed Army Institute of Research,
Silver
Spring, MD. Manage basic research effort s of Biology, Microbiology, Pharmacology,
Medicinal Chemistry and Chemical Information with a total staff of 101 (10 MDs, 39
PhDs) and budget of $14 million including $2.2 million extramural contract program.
1999-2002 Additional Duties as Microbiology Consulta nt to the Surgeon General of the
Army.
Provided microbiological expertise, career ma nagement and graduate medical education
opportunities for globally assigned commissioned officers in clinical or research
disciplines of medical microbiology. Assisted in coordinating regional DoD medical
centers with Laboratory Response Network (LRN) through local, state and CDC health
authorities, USA Medical Research Unit-Brazil (USAMRU-B), Special Foreign
Activity,
Walter Reed Army Institute of Research. Direct, support and perform basic and applied
research, clinical trials and patient diagnosis in a multi-disciplinary program to
develop
new diagnostics and drug and vaccine candidates for emerging diseases. Successfully
negotiated international health treaty entitled "Implementing Arrangement, Relating to
Health, of the Agreement Relating to Coop eration in Science and Technology Between
the Government of the Federative Republic of Brazil and the Government of the United
States of America, 1995."
1990-1992 Department Chair, Division of Experimental Therapeutics, Walter Reed Army
Institute of
Research. Direct, support and perform basic and translational research. Program and
research contract manager for basic and applie d research and pre-clinical efficacy
testing
at laboratories in the United States, India, Thailand, Panama and the United Kingdom.
Member or Chair, WRAIR Human Use/Scientific Review Protocol Committees for
vaccine and drug protocols.
1987-1990Integrated Research Team Leader, Division of Experimental Therapeutics, WRAIR.
Link basic and translational research in drug discovery and design to lead optimization.
1983-1987Chief, Malaria Research Lab, Division of Experimental Therapeutics, in support
of basic
research in drug discovery and drug resistance.
2
Curriculum Vitae, Wil Milhous
January 2008
1980-1983Graduate Research Assistant (Burroughs Wellcome Scholar) School of Public
Health,
University of North Carolina, Chapel Hill, N.C. Teaching assistant in medical mycology
& medical parasitology at UNC.
Pre-Doctoral Experience (NRM Specialist in Public Health & Medical Lab Microbiology)
Clinical Microbiologist, Chief, Microbiology and Parasitology, Department of Pathology
Womack Army Hospital (500 beds),
Ft. Bragg, NC, 1975-1980
Clinical Laboratory Officer, and Chief, Microbiology and Immunology, Department of
Pathology, US Army Hospital (300 beds
)
Ft. Polk, LA, 1973-1975
Post Graduate Training
National Institutes of Health, Bethesda, MD
Fellows Training Rotation in Medical Microbiology, 1990
Duke University Medical Center, Durham, NC, 1981
Medical Mycology
Medical Immunology
Centers for Disease Control, Atlanta, GA
Molecular Epidemiology
Clinical Microbiology in Control of Nosocomial Infections
Dark field Microscopy of Treponema pallidum
Microbiology of the Hospital Environment
Laboratory Methods in Intestinal Protozoa
Laboratory Methods in Medical Mycobacteriology
Laboratory Methods in Anaerobic Bacteriology
Laboratory Methods for Diagnosis of Gonorrhea
Laboratory Methods for Detection of Legionnaires Disease Agent
Laboratory Methods in Special Medical Microbiology
University of North Carolina, Chapel Hill, NC, 1977-1979 (Part-time Off-Campus MPH
Program)
33 Graduate Credits in Epidemiology, Biostatis tics, Environmental Science,
Grantsmanship,
Health Administration, Program & Budgeting, Hea lth Structure, Health Policy & Law
declared as
minor in full time doctoral program (1980-1983).
Good Clinical Practices
FDA-Regulated Electronic Documents (FRED), 2008
Principles of Clinical Data Management (CDM), 2006
USA Medical Research & Materiel Command, Re gulatory Affairs Investigator Training, 2004
National Institutes of Allergy and Infectious Disease, 2003
University of Wisconsin School of Pharmacy, 1995
Pharmaceutical Education & Research Institute
Project Management in the Research -Based Pharmaceutical Industry, 1996
Honors and Awards
Faculty Fellows Program Award, Patel Center for Global Solutions, USF, 2007
Pharmaceutical Achievement Award for Social Responsibility, presented to the Institute
for
OneWorld Health, 2005, Advisory Board Member.
USA Research & Development Award for Small Business Innovative Research, 2000
USA Research & Development Achievement Award, 2000, for assisting in the development and
FDA approval of Glaxo SmithKline Malarone.
3
Curriculum Vitae,
Wil Milhous
January 2008
Bailey K. Ashford Medal, 1993, the American Society of Tropical Medicine and Hygiene for
distinguished work in tropical medicine for basic research contributions in drug
discovery
and drug resistance.
The Gorgas Medal, 1988, Association of Military Surgeons of the US (PHS, VA, DoD) for
notable contributions in prevention medicine through methods development and initiation
and establishment of the DoD Science and Technology Objective for Global Surveillance
and Detection of Drug Resistant Malaria.
USA Research & Development Achievement Award, 1988, for discovery of resistance modulator
drugs.
BG Greenberg Award for Public Health Research, 1984, UNC School of Public Health, methods
development in malaria susceptibility testing for antifolate drug combinations.
Finalist, MEPHA International Pri ze in Malaria Chemotherapy, 1994
Directors Award, Walter Reed Army Institute of Research, 1992
Delta Omega (Honorary National Public Health)
Gamma Sigma Delta (Honorary Agriculture)
Sigma Xi (The Scientific Research Society)
Mu Beta Psi (Honorary Music)
Military Awards
USA Legion of Merit, 2002
USA Medical Department Medallion, 2002
Order of Military Medical Merit, 1992 A" Proficiency Designator Award, Office of the Surgeon General, 1989
USA Meritorious Service Medals (4) 1997, 1995, 1991, 1979
The Expert Field Medical Badge, 1984
USA Achievement Medal, 1986
USA Commendation Medal, 1976
Armed Forces Reserve Medal, 1983
Army Service Ribbon
Overseas Service Ribbon
National Defense Service Medals (3)
Teaching Experience
2007- Rollins School of Public Health, Emory University, Atlanta, Georgia
GH 590R- Malaria: A Global Public Health Concern
1985-2007 WRAIR Formal, accredited training programs
Preventive Medicine Residency
Laboratory Animal Medicine Residency
Clinical Pharmacology Fellowship
1985-2007 WRAIR Postdoctoral programs
Medical Research Fellowship
National Research Council Post-Doctoral Associateships
1985-2007 WRAIR Community Outreach Programs
Gains in the Education of Mathematics and Science, ages 13-18
Science and Engineering Apprenticeship Program-SEAP for high school students
College Student Leadership Program-CQL for college students
Science for Elementary Teachers Program for teachers of grades 3 through 6
4
Curriculum Vitae, Wil Milhous
January 2008
1990-2007Adjunct Associate Professor
(
Assistant1984-1990) Uniformed Services University
of
the Health Sciences, Bethesda.
Medical Microbiology/Parasitology for Medical Students (16 semesters)
Chemotherapy/Pharmacology for MPH/PhD Students (5 semesters)
Scientific Mentor, Clinical Pharmacology Fellowship Training Program
1993-1996Visiting Scientist, Foundation of the In stitute of Oswaldo Cruz, Rio de
Janeiro
1989-presentAdjunct Assistant Professor, University of North Carolina, Department of
Parasitology &
Laboratory Practice (Epidemiology), School of Public Health
1991-1992Adjunct Assistant Professor, Bowling Green State University, Bowling Green, OH.
Allied Health Research Advisor
1991-presentVisiting Professor, Tropical Infectious Diseases, Central Military Hospital,
Bogota,
Columbia
1984-1992Walter Reed Army Institute of Research, WRAIR Postgraduate Course in Tropical
Medicine
1988-1991Montgomery College, Takoma Park, MD (evenings part time) Microbiology 203 for
Nursing & Medical Technology Students
(3 semesters)
1982 University of North Carolina, School of Public Health, Medical Mycology Laboratory
1981-1982UNC and Duke Schools of Medicine, Medical Parasitology Laboratory (2 semesters)
Fellows/Graduate Students/Research Training
Fogarty Foundation
Christian Happi, PhD, 2005-
Infectious Disease Fellows
Cindy Tamminga, MD, 2006-
Peter J. Weina, MD, PhD, 2001-2002Clinical Pharmacology Fellows
Colin Ohrt, MD, MPH 1995-1997
Mike Riel, MD 2000-2002
Kevin Canard, MD, 2004
-
David Sanders, MD, 2005
-
National Research Council Postdoctoral Fellows
Malcolm Gardner, PhD, 1991-1993
Dibyendu De, PhD, 1991-1993
David Wesche, MD, PhD, 1988-1990
World Health Organization Postdoctoral Fellows
Mariano Zalis, PhD
Graduate Students
Julia C. Mead, MPH, 2007. Funding Drugs Used to Combat Global Health Diseases. (Columbia
University Mailman School of Public Health, Thesis Advisor)
Adaymee Cofresi, MS, 2007. Increasing Parasitemia Modulates In Vitro Concentration
Response
to Artemisinin Drugs: Can Parasite Burden Alter Treatment Outcomes in Severe and
Complicated Malaria? (George Washington University, Washington, DC. Thesis
Advisor).
Cindy Tamminga, MD, MPH, 2007, Plasmodium falciparum infection among US Marines
deployed to Liberia: comparison of mefloquine resistance patterns to archived Liberia
isolates and previous studies (Uniformed Services University, Bethesda, MD. Thesis
Advisor).
5
Curriculum Vitae,
Wil Milhous
January 2008
Glorimar Alvardo, MS, 2003. Investigation of the antimalarial activity of Cissampelos
pareira
L. (Menispeermacae) (University of Puerto Rico, Committee Member)
Lyndale Emerson, PhD, 2001. Genetic and Transcriptional Profile Analyses in Saccharomyces
cerevisiae Reveal Role for Quinoline-Ring Antimalarial Drugs in Iron Uptake. (Harvard
School of Public Health Dissertation Examination Committee)
Michael Libby, MS, 1991. Erythrocyte Age and Dose Response. (Bowling Green University,
Advisor for Blood Bank Fellowship)
Sheila Peel, PhD, 1991. Mefloquine Resistance in Multidrug Resistant Plasmodium
falciparum in
vitro.(University of North Carolina, Committee Member)
Member, Professional Education and Training Committee for Graduate Medical Education
Walter Reed Army Institute of Research (1999-2003):
Preventive Medicine Residency Program
Clinical Pharmacology Fellowship
Laboratory Animal Medicine Residency Program
Military Medicine Fellowship Program
Research Support Pending:
PI: RFA-TW-08-001 Framework Programs for Global Health (R25) Global Health Innovations
Co-PI RFA-AI-07-025 Pharmacological Approaches to Combating Antimicrobial Resistance
(R01)
2008 Florida Centers of Excellence Competition, Advisory Board Member & Collaborator
The Comprehensive Drug Development Center (CDDC)
Florida Center of Computational Biology (FCCB)
Research Support:
C o-PI: Drug Resistance Networks in Kenya, Peru, Thailand, Ghana. DoD-GEIS GM0056_07WR
$800K, 2002-08.
Co-PI: Development of safer drugs for malaria and leishmaniasis in US troops, civilian
personnel and
travelers 12 Sep-11 Oct 2009. $1,916,303.ERMS # 07213002. PR: W23RYX7226N601
Senior Advisor: Antimalarial Drug Resistance Workshops. Bill & Melinda Gates Foundation
Global
Health Program Conference Grant, Cambridge, UK and Amsterdam, Netherlands. 3/15/2006-
$158, 173
Senior Advisor: Worldwide Antimalarial Drug Resistance Network (WARN). Bill & Melinda
Gates Foundation Global Health Program, 6/22/07- $998,100
Advisory Board: 1 D43 TW007990-01 IPF:513807 Program in Adolescent HIV/AIDS Research
Training (PAHRT) PI: Emmanuel, Patricia J. 09/11/2007 06/30/2012 $1.4 million
Consultant: Harvard School of Public Health
Fogarty International Research Training Grant. "T raining in Malaria Pathogenesis and
Diversity in
Africa" D43 TWOO1503 4/1/07 - 3/31/2010 $133,950.
Fogarty International Research Collaboration Awa rd (FIRCA). "Molecular determinants of
drug
resistant malaria in Nigeria" NIH R03 TW006298. 1/15/2004-12/31/2006 (extended through
12/31/07).
Senior Advisor and Co-PI: Optimization of Radical Curative and Causal Prophylactic Drugs,
Medicines for Malaria Venture, Geneva, Switzerland; $3 Million, 2006-7.
Senior Advisor: Development of Third Generation Macrolides, Pliva Pharmaceutical, Zagreb,
Croatia,
and Medicines for Malaria Venture, Geneva, Sw itzerland; Funding and Agreement TBA, 2007.
Senior Advisor: Lead Optimization and Pre-Clini cal Studies of Imidazolidinedione
Derivatives, Peer
Reviewed Medical Research Program (PRMRP), $3 Million, 2005-2007
6
Curriculum Vitae, Wil Milhous
January 2008
Previously Funded:
Research Coordinator, Senior Advisor, Military Infectious Disease Research Program, $48
Million, 2002-
2007
Senior Advisor: NIAID Challenge Grant: Joint Ventures in Biomedicine and Biotechnology
1RC
AI48874-01; WRAIR-SmithKline Beecham: Tafenoquine, new drug for malaria treatment and
control; $7.3 million, 2001-2006
Senior Advisor: NIAID Challenge Grant: Joint Ventures in Biomedicine and Biotechnology
1RC
AI48859-01. WRAIR-Pfizer: Azithromycin Combination Treatments; $600K, 2001-2006.
Co-PI: Artesunate for Severe and Complicated Malaria, Medicines for Malaria Venture,
Geneva,
Switzerland; 2003 ($800K), 2004 ($620K)
Associate Program Leader: NIAID/Fogarty Inte rnational Cooperative Biodiversity Group
(ICBG)
Program for West and Central A frica TW00327, $3 million, 2000-2005
Principal Investigator (PI): World Health Organization, Special Program for Research and
Training in
Tropical Diseases (TDR), Chemotherapy of Malaria (CHEMAL), ($230K), 1994-($82K), Co-PI 1996-2002 ($382K)
PI: Human metabolism of arteether, WHO TDR CHEMAL 1997-2000 ($178K).
PI: Analysis of arteether and related drugs in clinical samples WHO TDR CHEMAL, 1997-2001
($320K).
Co-PI:
Harvard University School of Public Health; Surveillance & Detection of Drug
Resistant Malaria,
NIAID International Center for Tropical Disease Research (ICIDR), 1995-2000.
Co-PI: Optimization of Sequencing Strategies for the Malaria Genome, Joint NIAID and DOD
Sponsored, 1997-2002 ($3 million).
PI: WRAIR Independent Research Awards, 1993-94 ($68K), Co-PI 1986-92 ($220K).
Sponsor: Rockefeller Foundation Biotechnology Fellowship, 1990-1992 ($60K).
Sponsor: Molecular Basis of Resistance in Falciparum Malaria. WHO TDR, 1994-6 ($50K).
Co-PI: Characterization of West African Isolates of Falciparum Malaria WHO TDR, 1986-92
($240K).
Co-PI: Drug Combinations in Chemotherapy, WHO TDR CHEMAL, 1992-95($200K).
Co-PI: Pharmacokinetics and metabolism of ar teether. WHO TDR CHEMAL, 1988-92 ($130K).
Co-PI: Sporontocidal Properties of WR238605, WHO TDR CHEMAL, 1989-92 ($120K).
Editorial Positions and Appointments
7
Curriculum Vitae,
Wil Milhous
January 2008
Committee Assignments and Administrative Experience
2007- Executive Scientific Advisory Committee, Medicines for Malaria Venture, Geneva,
Switzerland
2004- National Institutes of Allergy and Infectious Diseases (NIAID)
Infectious Diseases and Microbiology
Drug Discovery and Mechanisms of Antimicrobial Resistance ZRG1 DDR 01
Novel HIV Therapies: Integrated Pre-clinical/Clinical Program ZAI1-HSD-A-JI
Special Emphasis Panel/Scientific Review Group 2006/05 ZRG1 IDM-M (02), Feb 13
Special Emphasis Panel/Scientific Re view Group 2006/05 ZAI1-AC-M-C1, May 4
Special Emphasis Panel/Scientific Revi ew Group 2005/04 ZRG1 IDM-M (03), Mar 18
2006-
Stakeholder, Ten Years Strategy & Vision, Strategic and Discovery Research (SDR)
UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in
Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland
2005- Malaria Global R&D Alliance: Advisory Board Member and expert in malaria and global
tracking. Guided the development of survey instrument and reviewed final report for the
following funding recommendations from th e Bill and Melinda Gates Foundation:
$107.6 million to the PATH Malaria Vaccine Initiative (MVI) to work with
GlaxoSmithKline Biologicals and African investigators to complete testing and
apply for licensure of the most advanced malaria vaccine candidate
$100 million to the Medicines for Malaria Venture (MMV) to work with public
and private sector partners to accelerate the development of several promising
new drugs through regulatory approval
$50.7 million to the Innovative Vector Control Consortium (IVCC), led by the
Liverpool School of Tropical Medicine, to fast-track development of improved
insecticides and other mosquito control methods
2005- Advisory Committee, Novel Macrolides, Pliva Research Institute, Zagreb, Croatia
2004- National Institutes of Allergy and Infec tious Diseases (NIAID). Summits on
Infectious
Disease Therapeutics, DoD representative, 2000, 2004
2004National Academies, Board on Global Health, July 21-22, Washington, DC. Opinion
Leader for Malaria Control: A Reconsideration of the Role of DDT
2004 National Academies, Institute of Medicine . Contributor: Research and Development
for
New Antimalarial Drugs. In: Saving Lives, Buying Time: Economics of Malaria Drugs
in an Age of Resistance, 2004
2003-presentAdvisory Board, National Center fo r Natural Products Research, University
of
Mississippi, School of Pharmacy
2003-presentKey Opinion Leader (KOL), Glaxo SmithKline Pharmaceuticals, Immune Status
and
Causality of 8-Aminoquinolines
2000-presentExpert Advisory Panel, US Pharmacopoeia
1998-presentChair
(
2006) International Board of Di rectors, the Malaria Foundation
International
8
Curriculum Vitae, Wil Milhous
January 2008
2000-02Board of Advisors, American Type Culture Collection (ATCC)
1999-present Tafenoquine Steering Committee and Global Advisory Panel, Glaxo SmithKline
Pharmaceuticals
1999-present Advisory Committee, Food and Drug Administration, FDA-CBER,
Biological
Therapeutics
2001-present Advisory Committee, Institute for On e World Health (IOWH), San Francisco,
CA,
1997-02 Steering Committee, Drug Discovery R esearch (DDR) for Malaria, Tuberculosis,
Leishmania, and African Trypanosomiasis, Chagas Disease, Filariasis, Tropical Disease
Research (TDR) World Health Organization
2002-05Screeners Committee, WHO-TDR
1998-04Associate Program Leader: NIAID/Fogarty International Cooperative Biodiversity
Group (ICBG) Program for West and Central Africa
1987-presentSenior Research Advisor,
National Research Council
1998-presentRockefeller Foundation, Medicines for Malaria Venture (MMV) Planning Group,
1999
Organizer or Participant, Rockefeller Foundation Interdisciplinary, Intercultural Working
Groups, Bellagio, Italy
Lactate Dehydrogenase in Malaria, 1994
Public Health Applications of Improved Diagnostics, 2001
Applications of Genomics in Discovery of Drugs for Tropical Diseases, 2005
1997- Multilateral Initiative on Malaria (MIM) Working Groups: Dakar, Senegal; The Hague,
Netherlands; Durban, South Africa: Arusha, Tanzania; Stockholm, Sweden; Yaounde,
Cameroon. Participants: Pasteur Institute ; Commission of the European Communities;
the Wellcome Trust; Medical Research Council; World Health Organization; Centers for
Disease Control and Prevention; Netherlands Organization for Scientific Research
1990-1992National Academy of Sciences, Institute of Medicine, Washington, DC. Member,
United
States Committee on Malaria Prevention and Control.
1987- Member & Co-Founder, US Interagency (W RAIR, Department of State, Peace Corps,
CDC & FDA) Chemoprophylaxis Working Group
1990-1992 Member, Preventive Medicine Problem Definition & Assessment Team, Operation
Desert Storm
1987- National Institutes Allergy and Infectio us Disease, Study Section Special Member
Tropical Medicine & Parasitology 1987, 1989, 2004
Opportunistic Infections, 1997
2004- Reviewer, US-Israel Binational Science Foundation.
1985-1992 Member, Biotechnology/Parasitology Stud y Panel, Program for Science &
Technology
Cooperation, Agency for International Development, Chairman, 1987
9
Curriculum Vitae,
Wil Milhous
January 2008
Research Compliance and Regulatory Affairs for Investigational New Drug/New Drug
Applications
(* Discussion or pre-clinical efficacy leader for FDA-Special Pathogens type A,B,C
meetings)
WR= Walter Reed Number)
WR006026 (GSK-Sitamoqiune) Program Director and Co-PI, Phase II Clinical Trials in Brazil
WR100553 (Doxycycline-Pfizer-Vibramycin) Pre-Clinical Efficacy, Support Phase II and
Phase
III in Thailand
WR149240 (Mefloquine-HLR-Lariam) Pre-Clinical Efficacy/Resistance/Support Clinical
Trials,
Post Marketing Surveillance and Adverse Events
WR171669 (Halofantrine-GSK-Halfan) Pre-Clinical Efficacy/Resistance/Support Clinical
Trials
*WR238605 (GSK-Tafenoquine) Pre-Clinical Effi cacy and Supporting Phase I, Program
Director
Phase II, for Indonesia, East Timor, and Kenya
WR245567 (Sulfadoxine/Pyrimethamine-Roche-Fansidar) Post Marketing Surveillance,
Resistance, Adverse Events.
*WR255131 (Arteether-Artecef-Artemotil) PI, Pre-Clinical Efficacy and Phase III PK
Analysis
WR255663 (Artelinic Acid) Co-Inventor, Pre- Clinical Efficacy, FDA Consultations on
Neurotoxicity, Program Director
*WR256343 (IND 64769), Intravenous Arteusnate for Severe Malaria, Pre-Clinical Efficacy
Integrated Product Development Team
WR279277 (Pfizer-Azithromycin-Zithromax combinations) Co-Inventor, Pre-Clinical Efficacy,
Program Director for Phase III in Indonesia, Peru and Thailand.
WR279396 Topical Antileishmanial, Program Director
WR279825/WR003091 (Atovaquone /Proguanil GSK-Malarone) Pre-Clinical Efficacy/Resistance
and Co-PI for Phase III Clinical Trial in Brazil
Malaria Rapid Diagnostic Device (MRDD), Lead Optimization, Platform Selection, Support
Clinical Trials for 510K Application.
Membership in Societies:
American Society for Microbiology
American Society for Clinical Pharmacology and Therapeutics
American Society for Clinical Pathology
American Society for Microbiology
Invited Symposium: Managing R&D Portfolios in Antimicrobials and Diagnostics, 2008
Invited Symposium: Careers in Microbiology; Opportunities in Government, 2002.
American Academy of Microbiology
Tellers Committee, 1998-2002
Chair, Scherago-Rubin Award Committee, 2007; Member 2006
American Board of Medical Microbiology, Examination and Standards Committee, 1998-Presen
International Congress of Pharmacology : Chairman, Symposium on new approaches to
the treatment of malaria, 2002
American Society of Pharmac ognosy, Invited Symposia, 1991, 1995
American Society of Tropical Medicine and Hygiene, 1982-present,
Wil Milhous
January 2008
Malaria Chemotherapy, London School of Tropical Medicine & Hygiene, London, UK 1987-90
.
Methods for Diagnosis of Falciparum Malaria, SBIR I & II, 1998-2001
New Drugs for Malaria and African Trypanosomiasis, USUHS, 1985-90
Pharmacodynamics and pharmacokinetics and acute toxicology studies, Southern Research
Institutes, Birmingham Alabama, 1995-2002
Pre-formulation studies and formulation production,
University of Iowa, Ames, Iowa, 1995-
2004
Preparation of chemicals and bulk drugs,
Starks Associates, Buffalo, NY, 1995-2005
Preparation of radio-labeled compounds, Research Triangle Institute, RTP, NC, 1995-2004
Radical curative testing in primates, AFRIMS, Bangkok, Thailand,
1984-
Synthesis and Screening of Antimalarial Drugs, Cent ral Drug Research Institute,
Lucknow,
India, 1985-
1998 (Department of StateUS India Fund
)
11
Curriculum Vitae, Wil Milhous
January 2008
Patents and Invention Disclosures
US Patent Office -15
European Patent Office-4
World Intellectual Property Organization (WIPO)-6
1. Serial No. 11/644,494 filed 12/21/2006. Synthetic ar temisinins in the clinical and
veterinary
management of kinetoplastid infections.
2. 7,101,902. September 5, 2006. 2-guanidinylimidazolidinedione compounds and methods of
making and using thereof. 200-***-****. European 04821254. 2-2107.
7,084,132. August 1, 2006. Artemisinins with improved stability and bioavailability for
3.
therapeutic drug development and application.
4. 200********. January 29, 2004. Mixed steroida l 1,2,4,5-tetraoxane compounds and
methods
of making and using thereof. Serial No. 359584, February 7, 2003.
5. 200********. September 11, 2003. Intravenous form ulation of artelinic acid for
treatment of
severe and complicated malaria. Serial No. 376420, February 27, 2003.
200********. July 15, 2004. Fab I and inhibition of apicomplexan parasites. 6.
PCT/US01/49738 filed 12/20/2001; and U.S. Patent Application No. 10/465,527 filed
06/18/20037. 200********. March 18, 2004. Antimalarial activities and therapeutic properties of
febrifugine analogues. Serial No. 600446, Filed June 20, 2003.
200********. February 13, 2003. Chemosensitizing agents against chloroquine resistant 8.
Plasmodium falciparum and methods of making and using thereof. Serial No. 849400, May 7,
2002.PCT/US01/14574.
9. 4,791,135. December 13, 1988. Novel antimalaria l dihydroartemisinin derivatives.
Serial No.
087365, August 29, 1987.
10. 4,897,403. January 30, 1990. Antimalarial Compositions and Methods. Serial No.
936677,
filed November 18, 1986. European No. 8900622.7
11. Synergistic Combinations of Azithromyci n for Malaria Treatment, Filed May 2001
12. Prophylaxis Against Transfusion Acquired Chagas Disease, Filed June 1996
13. Treatment & Prophylaxis of Toxoplasmosis, Filed June 1997
14. Treatment & Prophylaxis of Puemoncystis Pneumonia Using 8-Aminoquinolines
Diamine Complexes of Silver Sulfonamides in Chemotherapy. File No. 77181 Sep 5, 1985 15.
12
Curriculum Vitae, Wil Milhous
January 2008
(Publications Sorted by Journal)
Acta Trop 95: 183-93.
Antimicrob Agents Chemother 51: 2898-904; 49:3463-7; 46:2627-32; 46:2518-24; 43:598-602;
38:1392-6; 36:2761-5; 36:1538-44; 35:277-82; 33:1090-4; 27:525-30.
Amer J Trop Med Hyg 75:155-61; 71:723-31; 70:20-6; 66:516-25; 65:685-9; 58:630-7; 58:625-
9; 52:
347-8; 50: 646-53,200-5;49: 485-91,473-7,121-6,113-20; 48: 377-84,126-33; 46:169-82;
45:98-
111; 44:553-9; 40:7-11; 39:15-20; 38:24-9; 36:9-14; 36:1-2;35:472-5
Ann Trop Med Parasitol: 97: 439-5187: 547-52; 100:571-8
Bioorg Med Chem 13: 699-704; 11: 2761-8.
Current Drug Therapy 2: 210-223
Cytometry A 71:297-307.
Drug Metab Dispos epud ahead of print
Exper Parasitol 87: 283-9; 76: 345-51; 72: 450-8; 67: 354-60; 87: 283-289
Euro J Med Chem 39: 59 67.
Heterocycles 31: 1011
Int J Pharmacog 31:255-258
Int J Parasitol 31: 109-13.
J Biomed Sci 9 :34-40
J Chem Inf Comput Sci. 42:1212-20; 37:124-30
J Inf Dis 185: S25-S36; 180: 1282-1287; 165: 764-8; 175: 1544-7; 165:764-8.
J Med Chem 50: 6226-31, 5118-27; 99: 3790-99; 48: 6472-81, 2805-13; 45: 3331-6; 43: 3274-
82,
2753-8, 1246-9, 41:4360-4; 38:5038-44.37:1256-8; 36:4264-75; 35:3023-7, 2459-67;
35:2129-34; 33:1516-8; 31:645-50; 30:2147-50.
J Nat Prod 65: 614-5; 56: 1954-61; 47: 715-7
J Serbian Chem 72: 1181-90; 69: 919-922; 68: 291-302
J Travel Med 7: 275-282
Lancet. 8571: 1304-5; 9287: 1066-7
Malaria Journal 5:82 doi:10.1186/147*-****-*-**.
Military Med: 170: 2-12; 154: 55-59
Mol Biochem Parasitol 57: 151-60
Nature 393: 801-805; 397: 219-220
Parasitol 134: 1151-62
Parasitol Today 14: 376-377; 9: 167-168
Prog Clin Parasitol 1: 21-56
100: . Parasitol Research: 100:141-8.
PNAS 87: 3018-22; 84: 7310-14
Science 242: 1301-3; 238: 1283-5; 235: 899-901
Trans Roy Soc Trop Med Hyg 87: 81-3; 86: 123-6; 85: 33-4; 84: 474-8; 88: 691-6; 83:308-10
13
Curriculum Vitae, Wil Milhous
January 2008
Publications Sorted by Date
1. Mui EJ, Schiehser G, Milhous WK, Hsu H, Roberts C, Jacobus D, Kirisits, M, Muench S,
Rice D, Dubey
JB, Fowble JB, Rathod PK, Quenner, SF, Lie SR, Jacobus DP and McLeod R. 2008. Novel
triazine JPC-
2067-B inhibits Toxoplasma gondii in vitro and in vi vo. PLoS Neglected Diseases
(accepted).
2. Li Q, Weina PJ and Milhous WK. 2007. Pharmacokinetic and pharmacodynamic profiles of
rapid-acting
astemisinins in antimalarial therapy. Current Drug Therapy 2:210-223
3. Guan J, Wang X, Smith K, Ager A, Gettayacamin M, Kyle DE, Milhous WK, Kozar MP, Magill
AJ, Lin
AJ. Malaria causal prophylactic activity of imid azolidinedione derivatives.J Med Chem.
2007 Nov
29;50(24):6226-31. Epub 2007 Oct 30. PMID: 17967003
4. Opsenica I, Opsenica D, Jadranin M, Smith K, Milhous WK, Stratakis M and olaja B.
2007. On peroxide
antimalarials. J Serb Chem Soc 72: 1181 1190.
5. Diaz DS, Kozar MP, Smith KS, Asher CO, Sousa JC, Schiehser GA, Jacobus DP, Milhous WK,
Skillman
DR, Shearer TW. The role of specific P450 isoforms in the conversion of
phenoxypropoxybiguanide
analogs in human liver microsomes to potent antimalarial dihydrotriazines. Drug Metab
Dispos. 2007 Nov
15; [Epub ahead of print] PMID: 18006651
Terzic N, Opsenica D, Mili c D, Tinant B, Smith KS, Milhous WK, Solaja BA. Deoxycholic
acid-derived 6.
tetraoxane antimalarials and antiproliferatives. J Med Chem. 2007 Oct 18;50(21):5118-27.
Epub 2007 Sep
21. PMID: 17887664
7. Li Q, Kozar MP, Shearer TW, Xie LH, Lin AJ, Smith KS, Si Y, Anova L, Zhang J, Milhous
WK, Skillman
DR. Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines
administered in single and
multiple doses in rats. Antimicrob Agents Chemother. 2007 Aug;51(8):28
Contact this candidate